♥

Morepen Laboratories Limited

ISIN : INE083A01026
NSE : MOREPENLAB
BSE : 500288
Face Value : 2
Industry : Pharmaceuticals & Drugs

EPS : 1.88
EPS (TTM) : 2.30
Price to Earning (P/E) : 25.45
Book Value : 16.58
Price to Bookvalue (P/B) : 2.89
Dividend Yield : 0 %
Return on Equity (ROE) : 12.08 %
Return on Capital Employed (ROCE) : 16.82 %

Morepen Laboratories share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	36.25 - 37.98 4.8 %
Low / High	35.18 - 38.26 8.8 %
Trade Volume	3.51 Lk
52 Week Low / High	33.44 - 70.4 110.5 %

YOU MAY ALSO LIKE

How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
Share Market basics for beginners
Share Market jargons in simple terms
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Stock market course tutorial
Stock Market Investment Course explained in simple words.

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR MOREPEN LABORATORIES LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	3682.84	3024.02	4029.78	3484.65	3636.85	4010.36	4217.69	4445.54	4230.73	4552.16
Total Income	3714.63	3033.15	4038.52	3496.88	3668.08	4034.56	4250.06	4486.25	4273.16	4586.43
Total Expenditure	3496.1	2878.56	3740.69	3279.45	3481.27	3749.48	3881.79	3939.87	3746.94	4035.96
Other Income	31.79	9.13	8.74	12.23	31.23	24.2	32.37	40.71	42.43	34.27
Operating Profit	218.53	154.59	297.83	217.43	186.81	285.08	368.27	546.38	526.22	550.47
Interest	7.96	3.95	4.74	5.5	5.62	2.83	4.58	21.72	7.98	11.52
PBDT	210.57	150.64	293.09	211.93	181.19	282.25	363.69	524.66	518.24	538.95
Depreciation	68.83	67.57	70.03	71.92	69.79	77.14	76.87	84.45	96.24	57.28
Profit Before Tax	141.74	83.07	223.06	140.01	111.4	205.11	286.82	440.21	422	481.67
Tax	18.53	26.77	64.96	50.07	28.99	58.79	74.26	120.3	134.61	119.98
Profit After Tax	123.21	56.3	158.1	89.94	82.41	146.32	212.56	319.91	287.39	361.69
Net Profit	123.21	56.3	158.1	89.94	82.41	146.32	212.56	319.91	287.39	361.69
Equity Capital	955.59	998.27	1022.27	1022.27	1022.27	1022.27	1022.27	1022.27	1022.27	1022.27
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	0.26	0.11	0.31	0.18	0.16	0.29	0.42	0.63	0.55	0.71
Diluted Eps After Extraordinary Items	0.24	0.11	0.33	0.16	0.16	0.29	0.42	0.63	0.54	0.71
Diluted Eps Before Extraordinary Items	0.24	0.11	0.33	0.16	0.16	0.29	0.42	0.63	0.54	0.71

STANDALONE QUARTERLY RESULT FOR MOREPEN LABORATORIES LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	3424.42	2743.97	3833.42	3446.19	3365.24	3691.03	3812.58	3946.33	3926	3856.43
Total Income	3455.51	2751.06	3842.17	3458.07	3395.12	3711.87	3840.95	3982.91	3965.86	3887.15
Total Expenditure	3232.64	2607.88	3562.59	3231.73	3213.95	3443	3514.96	3435.17	3364.64	3370.33
Other Income	31.08	7.09	8.74	11.87	29.88	20.84	28.38	36.58	39.86	30.72
Operating Profit	222.87	143.18	279.58	226.34	181.17	268.87	325.99	547.74	601.22	516.82
Interest	7.96	3.95	4.74	5.5	5.62	2.83	4.55	20.44	7.28	10.44
PBDT	214.91	139.23	274.84	220.84	175.55	266.04	321.44	527.3	593.94	506.38
Depreciation	48.2	43.71	44.64	45.57	46.14	48.93	48.1	55.08	66.88	35.9
Profit Before Tax	166.71	95.52	230.2	175.27	129.41	217.11	273.34	472.22	527.06	470.48
Tax	23.96	26.77	64.96	49.6	26.66	58.62	74.1	120.2	127.47	119.98
Profit After Tax	142.75	68.75	165.24	125.67	102.75	158.49	199.24	352.02	399.59	350.5
Net Profit	142.75	68.75	165.24	125.67	102.75	158.49	199.24	352.02	399.59	350.5
Equity Capital	955.59	998.27	1022.27	1022.27	1022.27	1022.27	1022.27	1022.27	1022.27	1022.27
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	0.3	0.14	0.32	0.25	0.2	0.31	0.39	0.69	0.78	0.69
Diluted Eps After Extraordinary Items	0.28	0.13	0.35	0.24	0.2	0.31	0.39	0.69	0.78	0.69
Diluted Eps Before Extraordinary Items	0.28	0.13	0.35	0.24	0.2	0.31	0.39	0.69	0.78	0.69

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR MOREPEN LABORATORIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	15468.3	14175.3	16904.3
Total Income	15571.3	14236.6	17044
Total Expenditure	14101.5	13380	15318.1
Other Income	103.07	61.33	139.71
Operating Profit	1469.79	856.67	1725.94
Interest	-73.66	19.81	37.1
PBDT	1543.45	836.86	1688.84
Depreciation	276.42	279.3	334.7
Profit Before Tax	1267.03	557.56	1354.14
Tax	250.21	170.8	387.95
Profit After Tax	1016.82	386.76	966.19
Net Profit	1016.82	386.76	966.19
Equity Capital	955.59	1022.27	1022.27
Face Value (IN RS)	2	2	2
Reserves	4830.03	6506.81	7449.99
Calculated EPS	2.13	0.76	1.88
Diluted Eps After Extraordinary Items	1.96	0.77	1.88
Diluted Eps Before Extraordinary Items	1.96	0.77	1.88

STANDALONE ANNUAL RESULT FOR MOREPEN LABORATORIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	14492.7	13388.8	15375.9
Total Income	14595	13446.4	15501.6
Total Expenditure	13201.3	12616.1	13757.8
Other Income	102.35	57.59	125.66
Operating Profit	1393.72	830.29	1743.84
Interest	-73.66	19.81	35.09
PBDT	1467.38	810.48	1708.75
Depreciation	211.95	180.06	219
Profit Before Tax	1255.43	630.42	1489.75
Tax	244.81	167.99	380.4
Profit After Tax	1010.62	462.43	1109.35
Net Profit	1010.62	462.43	1109.35
Equity Capital	955.59	1022.27	1022.27
Face Value (IN RS)	2	2	2
Reserves	5026.09	6778.87	7867.97
Calculated EPS	2.12	0.9	2.17
Diluted Eps After Extraordinary Items	1.94	0.92	2.17
Diluted Eps Before Extraordinary Items	1.94	0.92	2.17

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR MOREPEN LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	1188.06 Cr	1546.83 Cr	1417.53 Cr	1690.43 Cr
Sales	1175.37 Cr	1541.56 Cr	1413.95 Cr	1682.13 Cr
Net Sales	1188.06 Cr	1546.83 Cr	1417.53 Cr	1690.43 Cr
Increase/Decrease in Stock	-41.58 Cr	-10.04 Cr	16.48 Cr	2.11 Cr
Raw Material Consumed	776.87 Cr	990.39 Cr	883.74 Cr	1014.76 Cr
Opening Raw Materials	71.52 Cr	66.63 Cr	157.02 Cr	126.62 Cr
Purchases Raw Materials	567.78 Cr	818.56 Cr	695.48 Cr	856.1 Cr
Closing Raw Materials	66.63 Cr	157.02 Cr	126.62 Cr	144.96 Cr
Other Direct Purchases / Brought in cost	204.2 Cr	262.23 Cr	157.85 Cr	177 Cr
Power & Fuel Cost	13 Cr	18.93 Cr	23.78 Cr	34.09 Cr
Electricity & Power	13 Cr	18.93 Cr	23.78 Cr	34.09 Cr
Employee Cost	135.59 Cr	164.25 Cr	154.68 Cr	181.47 Cr
Salaries, Wages & Bonus	123.59 Cr	151.04 Cr	140.87 Cr	165.19 Cr
Contributions to EPF & Pension Funds	3.89 Cr	4.44 Cr	4.31 Cr	4.94 Cr
Workmen and Staff Welfare Expenses	3.68 Cr	3.73 Cr	4.32 Cr	4.83 Cr
Other Manufacturing Expenses	67.21 Cr	98.99 Cr	91.7 Cr	95.75 Cr
Repairs and Maintenance	4.44 Cr	7 Cr	7.79 Cr	9.64 Cr
Packing Material Consumed	45.26 Cr	68.96 Cr	55.52 Cr	45.56 Cr
General and Administration Expenses	34.71 Cr	42.38 Cr	55.44 Cr	66.63 Cr
Rent , Rates & Taxes	7.97 Cr	9.91 Cr	13.01 Cr	13.72 Cr
Insurance	1.34 Cr	1.56 Cr	1.42 Cr	2.05 Cr
Professional and legal fees	10.43 Cr	12.12 Cr	12.28 Cr	14.81 Cr
Traveling and conveyance	11.13 Cr	13.52 Cr	16.83 Cr	21.86 Cr
Selling and Distribution Expenses	49.66 Cr	53.58 Cr	66.17 Cr	109.98 Cr
Miscellaneous Expenses	34.08 Cr	51.67 Cr	46.01 Cr	27.02 Cr
Total Expenditure	1069.54 Cr	1410.15 Cr	1338 Cr	1531.81 Cr
Other Income	12.07 Cr	20.1 Cr	6.13 Cr	13.97 Cr
Interest Received	2.13 Cr	11.12 Cr	1.66 Cr	2.5 Cr
Operating Profit	130.58 Cr	156.77 Cr	85.67 Cr	172.6 Cr
Interest	1.79 Cr	2.43 Cr	1.98 Cr	3.71 Cr
PBDT	128.8 Cr	154.34 Cr	83.69 Cr	168.88 Cr
Depreciation	30.28 Cr	27.64 Cr	27.93 Cr	33.47 Cr
Profit Before Taxation & Exceptional Items	98.51 Cr	126.7 Cr	55.76 Cr	135.42 Cr
Profit Before Tax	98.51 Cr	126.7 Cr	55.76 Cr	135.42 Cr
Provision for Tax	1.42 Cr	25.02 Cr	17.08 Cr	38.8 Cr
Current Income Tax	1.43 Cr	25.28 Cr	16.82 Cr	39.32 Cr
Deferred Tax	0	2.48 Cr	20.34 Lk	-43.65 Lk
Profit After Tax	97.09 Cr	101.68 Cr	38.68 Cr	96.62 Cr
Minority Interest	-41,000	14,000	-3,000	-46.04 Lk
Consolidated Net Profit	97.09 Cr	101.68 Cr	38.68 Cr	96.16 Cr
Profit Balance B/F	-42.43 Cr	54.65 Cr	151.34 Cr	190.01 Cr
Appropriations	54.65 Cr	156.34 Cr	190.01 Cr	286.17 Cr
Earnings Per Share	2.16	2.13	0.76	1.88
Adjusted EPS	2.16	2.13	0.76	1.88

STANDALONE PROFIT / LOSS FOR MOREPEN LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	1112.42 Cr	1449.27 Cr	1338.88 Cr	1537.59 Cr
Sales	1101.72 Cr	1446.05 Cr	1335.48 Cr	1529.43 Cr
Net Sales	1112.42 Cr	1449.27 Cr	1338.88 Cr	1537.59 Cr
Increase/Decrease in Stock	-41.98 Cr	1.74 Cr	16.54 Cr	5.13 Cr
Raw Material Consumed	733.34 Cr	919.84 Cr	830.96 Cr	899.6 Cr
Opening Raw Materials	71.52 Cr	66.63 Cr	157.02 Cr	126.62 Cr
Purchases Raw Materials	567.78 Cr	818.56 Cr	695.48 Cr	856.1 Cr
Closing Raw Materials	66.63 Cr	157.02 Cr	126.62 Cr	144.96 Cr
Other Direct Purchases / Brought in cost	160.67 Cr	191.68 Cr	105.07 Cr	61.84 Cr
Power & Fuel Cost	13 Cr	18.93 Cr	23.78 Cr	34.09 Cr
Electricity & Power	13 Cr	18.93 Cr	23.78 Cr	34.09 Cr
Employee Cost	123.2 Cr	150 Cr	146.19 Cr	160.28 Cr
Salaries, Wages & Bonus	112.13 Cr	138.15 Cr	133.18 Cr	145.54 Cr
Contributions to EPF & Pension Funds	3.2 Cr	3.54 Cr	3.78 Cr	3.96 Cr
Workmen and Staff Welfare Expenses	3.68 Cr	3.73 Cr	4.28 Cr	4.78 Cr
Other Manufacturing Expenses	66.82 Cr	98.96 Cr	91.66 Cr	95.5 Cr
Repairs and Maintenance	4.08 Cr	7 Cr	7.76 Cr	9.39 Cr
Packing Material Consumed	45.26 Cr	68.96 Cr	55.52 Cr	45.56 Cr
General and Administration Expenses	29.69 Cr	35.93 Cr	50.41 Cr	58.56 Cr
Rent , Rates & Taxes	7.03 Cr	8.84 Cr	11.98 Cr	12.2 Cr
Insurance	1.18 Cr	1.35 Cr	1.26 Cr	1.85 Cr
Professional and legal fees	9.63 Cr	10.72 Cr	10.99 Cr	13.53 Cr
Traveling and conveyance	8 Cr	9.73 Cr	14.3 Cr	16.8 Cr
Selling and Distribution Expenses	44.09 Cr	44.9 Cr	58.42 Cr	99.15 Cr
Miscellaneous Expenses	31.89 Cr	49.84 Cr	43.66 Cr	23.47 Cr
Total Expenditure	1000.05 Cr	1320.13 Cr	1261.61 Cr	1375.77 Cr
Other Income	11.77 Cr	20.03 Cr	5.76 Cr	12.57 Cr
Interest Received	2.13 Cr	11.12 Cr	1.66 Cr	2.48 Cr
Operating Profit	124.15 Cr	149.16 Cr	83.03 Cr	174.38 Cr
Interest	1.79 Cr	2.43 Cr	1.98 Cr	3.51 Cr
PBDT	122.36 Cr	146.74 Cr	81.05 Cr	170.88 Cr
Depreciation	28.11 Cr	21.19 Cr	18.01 Cr	21.9 Cr
Profit Before Taxation & Exceptional Items	94.25 Cr	125.54 Cr	63.04 Cr	148.98 Cr
Profit Before Tax	94.25 Cr	125.54 Cr	63.04 Cr	148.98 Cr
Provision for Tax	0	24.48 Cr	16.8 Cr	38.04 Cr
Current Income Tax	0	24.62 Cr	16.6 Cr	38.57 Cr
Deferred Tax	0	2.48 Cr	20.34 Lk	-43.65 Lk
Profit After Tax	94.25 Cr	101.06 Cr	46.24 Cr	110.94 Cr
Consolidated Net Profit	94.25 Cr	101.06 Cr	46.24 Cr	110.94 Cr
Profit Balance B/F	-19.29 Cr	74.96 Cr	171.03 Cr	217.27 Cr
Appropriations	74.96 Cr	176.03 Cr	217.27 Cr	328.2 Cr
Earnings Per Share	2.1	2.12	0.9	2.17
Adjusted EPS	2.1	2.12	0.9	2.17

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR MOREPEN LABORATORIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	98.51 Cr	126.7 Cr	55.76 Cr	135.42 Cr
Adjustment	31.96 Cr	19.46 Cr	27.9 Cr	34.2 Cr
Changes In working Capital	-78.18 Cr	-178.99 Cr	-158.28 Cr	-58.12 Cr
Cash Flow after changes in Working Capital	52.29 Cr	-32.83 Cr	-74.62 Cr	111.49 Cr
Cash Flow from Operating Activities	50.83 Cr	-57.76 Cr	-91.17 Cr	73.37 Cr
Cash Flow from Investing Activities	-70.35 Cr	-31.68 Cr	-46.51 Cr	-83.3 Cr
Cash Flow from Financing Activitie	47.27 Cr	63.85 Cr	143.54 Cr	5.2 Cr
Net Cash Inflow / Outflow	27.75 Cr	-25.58 Cr	5.86 Cr	-4.72 Cr
Opening Cash & Cash Equivalents	13.64 Cr	41.39 Cr	15.8 Cr	21.67 Cr
Closing Cash & Cash Equivalent	41.39 Cr	15.8 Cr	21.67 Cr	16.95 Cr

STANDALONE CASH FLOW FOR MOREPEN LABORATORIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	94.25 Cr	125.54 Cr	63.04 Cr	148.98 Cr
Adjustment	29.63 Cr	13.02 Cr	18.01 Cr	22.7 Cr
Changes In working Capital	-74.56 Cr	-180.56 Cr	-166.9 Cr	-56.96 Cr
Cash Flow after changes in Working Capital	49.31 Cr	-41.99 Cr	-85.84 Cr	114.72 Cr
Cash Flow from Operating Activities	49.31 Cr	-66.38 Cr	-102.12 Cr	77.36 Cr
Cash Flow from Investing Activities	-69.09 Cr	-22.64 Cr	-36.2 Cr	-83.6 Cr
Cash Flow from Financing Activitie	47.46 Cr	63.93 Cr	144.2 Cr	28.22 Lk
Net Cash Inflow / Outflow	27.68 Cr	-25.09 Cr	5.88 Cr	-5.96 Cr
Opening Cash & Cash Equivalents	12.79 Cr	40.47 Cr	15.38 Cr	21.26 Cr
Closing Cash & Cash Equivalent	40.47 Cr	15.38 Cr	21.26 Cr	15.3 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR MOREPEN LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	89.96 Cr	95.56 Cr	102.23 Cr	102.23 Cr
Equity - Authorised	130 Cr	130 Cr	200 Cr	200 Cr
Equity - Issued	89.97 Cr	95.57 Cr	102.23 Cr	102.23 Cr
Equity Paid Up	89.96 Cr	95.56 Cr	102.23 Cr	102.23 Cr
Face Value	2	2	2	2
Total Reserves	291.04 Cr	456.75 Cr	650.68 Cr	745 Cr
Securities Premium	167.4 Cr	231.8 Cr	369.79 Cr	369.79 Cr
Capital Reserves	2.7 Cr	2.7 Cr	21.45 Cr	21.45 Cr
Profit & Loss Account Balance	54.65 Cr	151.34 Cr	190.01 Cr	286.17 Cr
Reserve excluding Revaluation Reserve	291.04 Cr	456.75 Cr	650.68 Cr	745 Cr
Shareholder's Funds	424.75 Cr	578.56 Cr	752.91 Cr	847.23 Cr
Minority Interest	-45.93 Lk	-46.07 Lk	-46.04 Lk	0
Secured Loans	82.83 Lk	1.32 Cr	93.35 Lk	3.36 Cr
Deferred Tax Assets / Liabilities	0	2.48 Cr	2.69 Cr	2.25 Cr
Deferred Tax Assets	0	9.18 Cr	9.57 Cr	10.38 Cr
Deferred Tax Liability	0	11.67 Cr	12.26 Cr	12.63 Cr
Other Long Term Liabilities	3.83 Cr	3.45 Cr	3.52 Cr	4.5 Cr
Long Term Provisions	25.39 Cr	28.24 Cr	29.74 Cr	33.82 Cr
Total Non-Current Liabilities	30.06 Cr	35.5 Cr	36.88 Cr	43.93 Cr
Trade Payables	208.85 Cr	258.12 Cr	226.88 Cr	295.03 Cr
Sundry Creditors	208.85 Cr	258.12 Cr	226.88 Cr	295.03 Cr
Other Current Liabilities	174.38 Cr	169.97 Cr	54.86 Cr	58.51 Cr
Advances received from customers	1.85 Cr	5.62 Cr	1.46 Cr	1.54 Cr
Short Term Borrowings	15.32 Cr	16.13 Cr	23.18 Cr	23.49 Cr
Secured ST Loans repayable on Demands	15.32 Cr	16.13 Cr	23.18 Cr	23.49 Cr
Working Capital Loans- Sec	15.32 Cr	16.13 Cr	23.18 Cr	23.49 Cr
Short Term Provisions	5.25 Cr	12.24 Cr	16.24 Cr	25.02 Cr
Provision for Tax	1.49 Cr	5.09 Cr	6.5 Cr	13.18 Cr
Total Current Liabilities	403.8 Cr	456.46 Cr	321.16 Cr	402.04 Cr
Total Liabilities	858.15 Cr	1070.05 Cr	1110.5 Cr	1293.21 Cr
Gross Block	628.32 Cr	613.25 Cr	656.24 Cr	620.62 Cr
Less: Accumulated Depreciation	403.79 Cr	361.45 Cr	389.27 Cr	313.28 Cr
Net Block	224.52 Cr	251.8 Cr	266.97 Cr	307.35 Cr
Capital Work in Progress	1.96 Cr	14.15 Cr	17.01 Cr	24.45 Cr
Non Current Investments	1.08 Cr	0	0	1.3 Cr
Long Term Investment	1.08 Cr	0	0	1.3 Cr
Quoted	1.08 Cr	0	0	1.3 Cr
Long Term Loans & Advances	103.52 Cr	69.53 Cr	70.07 Cr	70.82 Cr
Other Non Current Assets	27.31 Lk	27.77 Lk	27.62 Lk	24.28 Lk
Total Non-Current Assets	331.36 Cr	335.75 Cr	354.33 Cr	404.16 Cr
Inventories	175.33 Cr	275.85 Cr	228.89 Cr	248.59 Cr
Raw Materials	66.63 Cr	157.02 Cr	126.62 Cr	144.96 Cr
Work-in Progress	43.66 Cr	35.82 Cr	38.65 Cr	37.41 Cr
Finished Goods	36.84 Cr	37.23 Cr	35.11 Cr	30.9 Cr
Stores and Spare	2.61 Cr	3.49 Cr	4.5 Cr	3.67 Cr
Sundry Debtors	181.98 Cr	250.64 Cr	263.25 Cr	324.94 Cr
Debtors more than Six months	0	5.81 Cr	160.97 Cr	15 Cr
Debtors Others	187.14 Cr	250.67 Cr	105.03 Cr	312.88 Cr
Cash and Bank	67.89 Cr	45.97 Cr	56.31 Cr	52.12 Cr
Cash in hand	12.08 Lk	9.84 Lk	24.78 Lk	16.97 Lk
Balances at Bank	67.77 Cr	45.87 Cr	56.06 Cr	51.95 Cr
Other Current Assets	10.01 Cr	5.29 Cr	7.15 Cr	16.44 Cr
Interest accrued and or due on loans	58.2 Lk	57.72 Lk	98.04 Lk	1.56 Cr
Prepaid Expenses	1.18 Cr	2.13 Cr	4.54 Cr	10.09 Cr
Short Term Loans and Advances	91.58 Cr	156.54 Cr	200.58 Cr	246.96 Cr
Advances recoverable in cash or in kind	68.92 Cr	117.59 Cr	166.38 Cr	215.93 Cr
Advance income tax and TDS	51,000	52.62 Lk	0	0
Total Current Assets	526.79 Cr	734.3 Cr	756.16 Cr	889.04 Cr
Net Current Assets (Including Current Investments)	122.99 Cr	277.84 Cr	435 Cr	487 Cr
Total Assets	858.15 Cr	1070.05 Cr	1110.5 Cr	1293.21 Cr
Contingent Liabilities	92.71 Lk	2.64 Cr	6.66 Cr	9.76 Cr
Total Debt	17.05 Cr	18.57 Cr	25.16 Cr	29 Cr
Book Value	8.47	11.56	14.73	16.58
Adjusted Book Value	8.47	11.56	14.73	16.58

STANDALONE BALANCE SHEET FOR MOREPEN LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	89.96 Cr	95.56 Cr	102.23 Cr	102.23 Cr
Equity - Authorised	130 Cr	130 Cr	200 Cr	200 Cr
Equity - Issued	89.97 Cr	95.57 Cr	102.23 Cr	102.23 Cr
Equity Paid Up	89.96 Cr	95.56 Cr	102.23 Cr	102.23 Cr
Face Value	2	2	2	2
Total Reserves	311.26 Cr	476.36 Cr	677.89 Cr	786.8 Cr
Securities Premium	167.4 Cr	231.8 Cr	369.79 Cr	369.79 Cr
Capital Reserves	2.7 Cr	2.7 Cr	21.45 Cr	21.45 Cr
Profit & Loss Account Balance	74.96 Cr	171.03 Cr	217.27 Cr	328.2 Cr
Reserve excluding Revaluation Reserve	311.26 Cr	476.36 Cr	677.89 Cr	786.8 Cr
Shareholder's Funds	444.97 Cr	598.17 Cr	780.11 Cr	889.02 Cr
Secured Loans	82.83 Lk	1.32 Cr	93.35 Lk	3.36 Cr
Deferred Tax Assets / Liabilities	0	2.48 Cr	2.69 Cr	2.25 Cr
Deferred Tax Assets	0	9.18 Cr	9.57 Cr	10.38 Cr
Deferred Tax Liability	0	11.67 Cr	12.26 Cr	12.63 Cr
Other Long Term Liabilities	2.05 Cr	1.96 Cr	1.96 Cr	42.9 Lk
Long Term Provisions	24.01 Cr	26.64 Cr	28.87 Cr	31.6 Cr
Total Non-Current Liabilities	26.89 Cr	32.41 Cr	34.45 Cr	37.65 Cr
Trade Payables	192.33 Cr	217.32 Cr	213.1 Cr	267.43 Cr
Sundry Creditors	192.33 Cr	217.32 Cr	213.1 Cr	267.43 Cr
Other Current Liabilities	164.37 Cr	159.63 Cr	39.79 Cr	38.66 Cr
Advances received from customers	1.19 Cr	3.42 Cr	0	0
Short Term Borrowings	15.32 Cr	16.13 Cr	23.18 Cr	23.49 Cr
Secured ST Loans repayable on Demands	15.32 Cr	16.13 Cr	23.18 Cr	23.49 Cr
Working Capital Loans- Sec	15.32 Cr	16.13 Cr	23.18 Cr	23.49 Cr
Short Term Provisions	3.6 Cr	9.61 Cr	14.91 Cr	23.05 Cr
Provision for Tax	0	4.56 Cr	6.5 Cr	13.18 Cr
Total Current Liabilities	375.63 Cr	402.69 Cr	290.98 Cr	352.64 Cr
Total Liabilities	847.5 Cr	1033.26 Cr	1105.54 Cr	1279.31 Cr
Gross Block	516.17 Cr	479.46 Cr	512.07 Cr	477.36 Cr
Less: Accumulated Depreciation	372.14 Cr	323.35 Cr	341.25 Cr	260.83 Cr
Net Block	144.02 Cr	156.11 Cr	170.82 Cr	216.54 Cr
Capital Work in Progress	1.96 Cr	14.15 Cr	17.01 Cr	24.45 Cr
Non Current Investments	118.78 Cr	117.8 Cr	117.84 Cr	126.18 Cr
Long Term Investment	118.78 Cr	117.8 Cr	117.84 Cr	126.18 Cr
Quoted	1.08 Cr	0	0	1.3 Cr
Unquoted	117.7 Cr	117.8 Cr	117.84 Cr	124.88 Cr
Long Term Loans & Advances	89.67 Cr	68.17 Cr	68.74 Cr	68.99 Cr
Other Non Current Assets	27.31 Lk	27.77 Lk	27.62 Lk	24.28 Lk
Total Non-Current Assets	354.71 Cr	356.5 Cr	374.69 Cr	436.4 Cr
Unquoted	117.7 Cr	117.8 Cr	117.84 Cr	124.88 Cr
Inventories	169.61 Cr	258.25 Cr	211.35 Cr	220.15 Cr
Raw Materials	66.63 Cr	157.02 Cr	126.62 Cr	144.96 Cr
Work-in Progress	43.66 Cr	35.82 Cr	38.65 Cr	37.41 Cr
Finished Goods	36.84 Cr	37.23 Cr	35.11 Cr	30.9 Cr
Stores and Spare	2.61 Cr	3.49 Cr	4.5 Cr	3.67 Cr
Sundry Debtors	155.52 Cr	221.87 Cr	255.47 Cr	316.89 Cr
Debtors more than Six months	0	3.07 Cr	6.73 Cr	8.79 Cr
Debtors Others	159.95 Cr	223.86 Cr	250.47 Cr	309.46 Cr
Cash and Bank	66.98 Cr	45.55 Cr	55.9 Cr	50.48 Cr
Cash in hand	11.74 Lk	8.38 Lk	24.68 Lk	15.59 Lk
Balances at Bank	66.86 Cr	45.46 Cr	55.66 Cr	50.32 Cr
Other Current Assets	9.8 Cr	5.07 Cr	4.97 Cr	16.28 Cr
Interest accrued and or due on loans	58.2 Lk	57.72 Lk	98.04 Lk	1.56 Cr
Prepaid Expenses	97.8 Lk	1.92 Cr	2.37 Cr	9.92 Cr
Short Term Loans and Advances	90.88 Cr	146.02 Cr	203.16 Cr	239.12 Cr
Advances recoverable in cash or in kind	68.4 Cr	109.16 Cr	170.05 Cr	214.49 Cr
Advance income tax and TDS	0	33.17 Lk	0	0
Total Current Assets	492.79 Cr	676.76 Cr	730.85 Cr	842.91 Cr
Net Current Assets (Including Current Investments)	117.16 Cr	274.07 Cr	439.87 Cr	490.27 Cr
Total Assets	847.5 Cr	1033.26 Cr	1105.54 Cr	1279.31 Cr
Contingent Liabilities	92.71 Lk	1.64 Cr	6.66 Cr	7.09 Cr
Total Debt	17.05 Cr	18.57 Cr	25.16 Cr	28.19 Cr
Book Value	8.92	11.97	15.26	17.39
Adjusted Book Value	8.92	11.97	15.26	17.39

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR MOREPEN LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	2.16	2.13	0.76	1.88
CEPS(Rs)	2.83	2.71	1.3	2.55
Book NAV/Share(Rs)	8.47	11.56	14.73	16.58
Tax Rate(%)	1.44	19.75	30.63	28.65
Margin Ratios
Core EBITDA Margin(%)	9.98	8.84	5.61	9.38
EBIT Margin(%)	8.44	8.35	4.07	8.23
Pre Tax Margin(%)	8.29	8.19	3.93	8.01
PAT Margin (%)	8.17	6.57	2.73	5.72
Cash Profit Margin (%)	10.72	8.36	4.7	7.7
Performance Ratios
ROA(%)	12.76	10.55	3.55	8.04
ROE(%)	29.2	21.79	5.93	12.08
ROCE(%)	27.13	24.86	8.4	16.82
Asset Turnover(x)	1.56	1.6	1.3	1.41
Sales/Fixed Asset(x)	1.72	2.49	2.23	2.65
Working Capital/Sales(x)	9.66	5.57	3.26	3.47
Efficiency Ratios
Fixed Capital/Sales(x)	0.58	0.4	0.45	0.38
Receivable days	49.1	51.04	66.16	63.5
Inventory Days	48.2	53.23	64.98	51.55
Payable days	66.26	86.93	98.32	93.67
Valuation Parameters
PER(x)	14.89	17.2	33.94	22.36
PCE(x)	11.35	13.52	19.71	16.53
Price/Book(x)	3.8	3.17	1.74	2.54
EV/Net Sales(x)	1.17	1.11	0.9	1.26
EV/Core EBITDA(x)	10.68	10.98	14.96	12.32
EV/EBIT(x)	13.91	13.33	22.2	15.29
EV/CE(x)	1.63	1.61	1.15	2.43
M Cap / Sales	1.22	1.13	0.93	1.27
Growth Ratio
Net Sales Growth(%)	39.27	30.2	-8.36	19.25
Core EBITDA Growth(%)	67.42	20.05	-45.36	101.47
EBIT Growth(%)	144.09	28.74	-55.29	140.97
PAT Growth(%)	189.14	4.73	-61.96	149.82
EPS Growth(%)	189.13	-1.4	-64.44	148.62
Financial Stability Ratios
Total Debt/Equity(x)	0.04	0.03	0.03	0.03
Current Ratio(x)	1.3	1.61	2.35	2.21
Quick Ratio(x)	0.87	1	1.64	1.59
Interest Cover(x)	56.09	53.22	29.15	37.5
Total Debt/Mcap(x)	0.01	0.01	0.02	0.01

FINANCIAL RATIOS (STANDALONE) FOR MOREPEN LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	2.1	2.12	0.9	2.17
CEPS(Rs)	2.72	2.56	1.26	2.6
Book NAV/Share(Rs)	8.92	11.97	15.26	17.39
Tax Rate(%)	0	19.5	26.65	25.53
Margin Ratios
Core EBITDA Margin(%)	10.1	8.91	5.77	10.52
EBIT Margin(%)	8.63	8.83	4.86	9.92
Pre Tax Margin(%)	8.47	8.66	4.71	9.69
PAT Margin (%)	8.47	6.97	3.45	7.21
Cash Profit Margin (%)	11	8.44	4.8	8.64
Performance Ratios
ROA(%)	12.49	10.75	4.32	9.3
ROE(%)	26.61	20.77	6.84	13.29
ROCE(%)	24.54	23.73	9.15	17.71
Asset Turnover(x)	1.47	1.54	1.25	1.29
Sales/Fixed Asset(x)	1.92	2.91	2.7	3.11
Working Capital/Sales(x)	9.5	5.29	3.04	3.14
Efficiency Ratios
Fixed Capital/Sales(x)	0.52	0.34	0.37	0.32
Receivable days	45.43	47.52	65.07	67.93
Inventory Days	49.56	53.88	64.01	51.22
Payable days	64.94	81.12	92.69	96.93
Valuation Parameters
PER(x)	15.34	17.3	28.39	19.38
PCE(x)	11.82	14.3	20.43	16.18
Price/Book(x)	3.6	3.06	1.68	2.42
EV/Net Sales(x)	1.26	1.19	0.96	1.38
EV/Core EBITDA(x)	11.25	11.54	15.44	12.2
EV/EBIT(x)	14.54	13.45	19.71	13.95
EV/CE(x)	1.65	1.67	1.16	2.32
M Cap / Sales	1.3	1.21	0.98	1.4
Growth Ratio
Net Sales Growth(%)	40.46	30.28	-7.62	14.84
Core EBITDA Growth(%)	68.03	20.15	-44.34	110.03
EBIT Growth(%)	143.44	33.25	-49.19	134.51
PAT Growth(%)	191.49	7.23	-54.24	139.9
EPS Growth(%)	191.49	0.94	-57.23	139.9
Financial Stability Ratios
Total Debt/Equity(x)	0.04	0.03	0.03	0.03
Current Ratio(x)	1.31	1.68	2.51	2.39
Quick Ratio(x)	0.86	1.04	1.79	1.77
Interest Cover(x)	53.71	52.75	32.83	43.45
Total Debt/Mcap(x)	0.01	0.01	0.02	0.01

SHARE HOLDING PATTERN FOR MOREPEN LABORATORIES LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	36.74	38.22	38.22	38.22	38.22	38.22	38.22	38.22	38.22	35.65
FII %	0.95	1.15	0.89	0.96	1.00	1.29	2.11	1.85	1.67	2.08
DII %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07
Public %	58.24	56.63	57.14	57.88	58.44	58.20	57.44	57.77	57.96	60.56

PEER COMPARISON FOR MOREPEN LABORATORIES LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR MOREPEN LABORATORIES

Exchange Date	Purpose	Book Closure Dates
BSE 11-Sep-2024	Book Closure - A.G.M.	22-Sep-2024 28-Sep-2024
BSE 11-Sep-2024	AGM - A.G.M.	28-Sep-2024 28-Sep-2024
BSE 07-Aug-2024	Board Meeting - Quarterly Results & Final Dividend	12-Aug-2024
BSE 14-May-2024	Board Meeting - Audited Results	21-May-2024
BSE 19-Feb-2024	Board Meeting - Inter alia, consider and approve the following matters: 1. To evaluate proposals for fund raising by the Company, by way of, inter-alia, issue of securities including equity shares or any other equity linked instruments or securities including nonconvertible debt instruments along with warrants and convertible securities other than warrants or any other eligible securities by way of, inter-alia, a...	22-Feb-2024
BSE 24-Jan-2024	Board Meeting - Quarterly Results	31-Jan-2024
BSE 26-Oct-2023	Board Meeting - Quarterly Results	02-Nov-2023
BSE 05-Sep-2023	Book Closure - A.G.M.	22-Sep-2023 28-Sep-2023
BSE 05-Sep-2023	AGM - A.G.M.	28-Sep-2023 28-Sep-2023
BSE 31-Jul-2023	Board Meeting - Quarterly Results	05-Aug-2023
BSE 09-May-2023	Board Meeting - Audited Results	16-May-2023
BSE 06-Feb-2023	Board Meeting - Quarterly Results	13-Feb-2023
BSE 02-Feb-2023	Name Change - Inter-alia, considered and approved to change the name of the company from ?MOREPEN LABORATORIES LIMITED? to ?MOREPEN LIMITED? or any other name as may be available and approved by the Registrar of Companies, accordingly amendment in Memorandum of Association of the company with respect to said change of name, subject to the necessary approvals of Stock Exchanges, members and others, as may be req...	02-Feb-2023
BSE 03-Nov-2022	Board Meeting - Quarterly Results	10-Nov-2022
BSE 02-Sep-2022	Book Closure - A.G.M.	21-Sep-2022 27-Sep-2022
BSE 02-Sep-2022	AGM - A.G.M.	27-Sep-2022 27-Sep-2022
BSE 22-Jul-2022	Board Meeting - Quarterly Results	29-Jul-2022
BSE 28-Apr-2022	Board Meeting - Audited Results	05-May-2022
BSE 20-Jan-2022	Board Meeting - Quarterly Results Inter alia, to consider and approve: (2) Variation/alteration of preference shareholders? rights, by converting said unlisted preference shares into Compulsorily Convertible Preference Shares and issuance of Equity Shares arising on conversion thereof, subject to the approval of preference shareholders, equity shareholders and such other regulatory, statutory authority(ies), as m...	08-Feb-2022
BSE 03-Nov-2021	Board Meeting - Quarterly Results	11-Nov-2021
BSE 07-Sep-2021	Book Closure - A.G.M.	22-Sep-2021 28-Sep-2021
BSE 07-Sep-2021	AGM - A.G.M.	28-Sep-2021 28-Sep-2021

CORPORATE ANNOUNCEMENTS FOR MOREPEN LABORATORIES

Exchange Date	Category File	Description
BSE 23-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find attached intimation of loss of share certificates
BSE 18-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find attached intimation of loss of share certificates
BSE 16-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find attached intimation of issuance of duplicate share certificate
BSE 14-Oct-2024	General Announcements FILE	General Update On Disclosure Submitted On August 27 2024. Please find enclosed update on disclosure submitted on August 27 2024.
BSE 11-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find attached intimation of loss of share certificate
BSE 28-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Please find enclosed e-Voting results along-with scrutinizers report for the 39th Annual General Meeting held on Saturday 28th September 2024 at 1.00 pm through VC/ OAVM.
BSE 28-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Please find enclosed proceedings of the 39th Annual General Meeting held through VC/ OAVM on Saturday 28th September 2024 at 1.00 p.m. (IST).
BSE 27-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Please find enclsoed intimation w.r.t. appointment of Mr. Amrit Ravi as Lead - Emerging Opportunities in the grade of Vice President being a Senior Management Personnel.
BSE 27-Sep-2024	Intimation FILE	Closure of Trading Window Please find attached letter w.r.t. closure of trading window w.e.f. 1st October 2024 till the 48 hours from the announcement of financial results for the quarter and half year ended on 30th September 2024.
BSE 24-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Please find attached press release
BSE 21-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find attached intimation of issuance of duplicate share certificates
BSE 21-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find attached intimation of loss of share certificates
BSE 19-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find attached intimation of loss of share certificate
BSE 18-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate Please find enclosed intimation for completion of tenure of Independent Directors namely Mr. Manoj Joshi Mr. Sukhcharan Singh and Mr. Bhupender Raj Wadhwa.
BSE 11-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find enclosed intimation of issuance of duplicate share certificate
BSE 11-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find enclosed intimation of loss of share certificate
BSE 09-Sep-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Please find enclosed Business Responsibility and Sustainability Report of the company for the financial year 2023-24.
BSE 05-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Please find enclosed newspaper publications with respect to dispatch of notice of 39th AGM including e-Voting details and annual report for the financial year 2023-24 via electronic mode on 4th September 2024.
BSE 04-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find enclosed intimation of loss of share certificate
BSE 04-Sep-2024	Intimation FILE	Book Closure For The Purpose Of 39Th Annual General Meeting Please find enclosed notice of 39th Annual General Meeting and details of book closures.
BSE 04-Sep-2024	Intimation FILE	Notice Of 39Th Annual General Meeting Please find enclosed notice of 39th Annual General Meeting and details of book closure.
BSE 04-Sep-2024	General Announcements FILE	Reg. 34 (1) Annual Report. Please find enclosed annual report for the financial year ended 31st March 2024 along-with notice of 39th Annual General Meeting.
BSE 27-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate Appointment of Mr. Sharad Jain as an Independent Director with effect from 27-August-2024.
BSE 27-Aug-2024	General Announcements FILE	Outcome Of Board Meeting Held On 27-August-2024. Please find enclosed letter comprising outcome of board meeting held on 27-August-2024.
BSE 26-Aug-2024	General Announcements FILE	Clarification Submission Please find enclosed response from the company.
BSE 23-Aug-2024	General -	Clarification sought from Morepen Laboratories Ltd The Exchange has sought clarification from Morepen Laboratories Ltd on August 23 2024 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.
BSE 17-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Please find attached Transcript of Earnings Conference Call Q1 FY 25
BSE 14-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find attached intimation of issuance of duplicate share certificates
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Please find enclosed weblink of the audio recording of analyst/ investors conference call held on 14th August 2024.
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Please find enclosed newspaper publication of Q 1 FY 25 results.

INSIDER TRADING FOR MOREPEN LABORATORIES

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 21-Sep-2022 21-Sep-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.63 %)	React Investments and Financial Services Pvt Ltd
BSE 21-Sep-2022 21-Sep-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.63 %)	Mid-Med Financial Services and Investments Pvt Ltd
BSE 21-Sep-2022 21-Sep-2022	Buy Conversion of security	5,000,000 @ 0.00 (0.00 %)	Liquid Holdings Pvt Ltd
BSE 30-Mar-2022 30-Mar-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.58 %)	Brook Investments and Financial Services Pvt Ltd
BSE 30-Mar-2022 30-Mar-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.59 %)	Epitome Holdings Pvt Ltd
BSE 30-Mar-2022 30-Mar-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.59 %)	Square Investments and Financial Services Pvt Ltd
BSE 30-Mar-2022 30-Mar-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.58 %)	Concept Credits and Consultants Pvt Ltd
BSE 30-Mar-2022 30-Mar-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.58 %)	Scope Credits and Financial Services Pvt Ltd
BSE 30-Mar-2022 30-Mar-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.59 %)	Seed Securities and Services Pvt Ltd
BSE 30-Mar-2022 30-Mar-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.58 %)	Solace Investments and Financial Services Pvt Ltd
BSE 30-Mar-2022 30-Mar-2022	Buy Conversion of security	3,500,000 @ 0.00 (0.58 %)	Solitary Investments and Financial Services Pvt Ltd

BULK BLOCK DEALS FOR MOREPEN LABORATORIES LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 07-Apr-2022	Buy BULK	2,405,735 @ 46.73	MBL & COMPANY LIMITED
BSE 07-Apr-2022	Sell BULK	1,994,735 @ 46.88	MBL & COMPANY LIMITED

DIVIDEND BY MOREPEN LABORATORIES LIMITED

No dividend details found

SPLIT / BONUS BY MOREPEN LABORATORIES LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Morepen Laboratories Limited

Morepen Laboratories share price

CONSOLIDATED QUARTERLY RESULT FOR MOREPEN LABORATORIES LIMITED

STANDALONE QUARTERLY RESULT FOR MOREPEN LABORATORIES LIMITED

CONSOLIDATED ANNUAL RESULT FOR MOREPEN LABORATORIES LIMITED

STANDALONE ANNUAL RESULT FOR MOREPEN LABORATORIES LIMITED

CONSOLIDATED PROFIT / LOSS FOR MOREPEN LABORATORIES LIMITED

STANDALONE PROFIT / LOSS FOR MOREPEN LABORATORIES LIMITED

CONSOLIDATED CASH FLOW FOR MOREPEN LABORATORIES LIMITED

STANDALONE CASH FLOW FOR MOREPEN LABORATORIES LIMITED

CONSOLIDATED BALANCE SHEET FOR MOREPEN LABORATORIES LIMITED

STANDALONE BALANCE SHEET FOR MOREPEN LABORATORIES LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR MOREPEN LABORATORIES LIMITED

FINANCIAL RATIOS (STANDALONE) FOR MOREPEN LABORATORIES LIMITED

SHARE HOLDING PATTERN FOR MOREPEN LABORATORIES LIMITED

PEER COMPARISON FOR MOREPEN LABORATORIES LIMITED

CORPORATE ACTIONS FOR MOREPEN LABORATORIES

CORPORATE ANNOUNCEMENTS FOR MOREPEN LABORATORIES

INSIDER TRADING FOR MOREPEN LABORATORIES

BULK BLOCK DEALS FOR MOREPEN LABORATORIES LIMITED

DIVIDEND BY MOREPEN LABORATORIES LIMITED

SPLIT / BONUS BY MOREPEN LABORATORIES LIMITED